Loading...
Docoh

Processa Pharmaceuticals (PCSA)

Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Company acquired the assets of Promet Therapeutics, LLC in October of 2017 and assembled a proven regulatory science development team, management team, and Board of Directors. The Processa drug development team members have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. PCS-499 represents the first Processa drug that can potentially be used in several unmet medical need conditions.

Company profile

PCSA stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
18 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 12.06M 12.06M 12.06M 12.06M 12.06M 12.06M
Cash burn (monthly) 776.84K 730.59K 1.72M 1.24M 776.84K 701.1K
Cash used (since last report) 1.28M 1.2M 2.84M 2.04M 1.28M 1.16M
Cash remaining 10.78M 10.86M 9.22M 10.02M 10.78M 10.91M
Runway (months of cash) 13.9 14.9 5.4 8.1 13.9 15.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Aug 22 Sian Bigora Common Stock Option exercise Acquire M No No 0 7,601 0 403,019
5 Aug 22 Wendy Guy Common Stock Option exercise Acquire M No No 0 7,601 0 189,528
5 Aug 22 Patrick Lin Common Stock Payment of exercise Dispose F No No 3.17 2,656 8.42K 438,335
5 Aug 22 Patrick Lin Common Stock Option exercise Acquire M No No 0 7,601 0 440,991
5 Aug 22 Geraldine Pannu Common Stock Option exercise Acquire M No No 0 1,169 0 11,269
5 Aug 22 James H Stanker Common Stock Payment of exercise Dispose F No No 3.17 2,462 7.8K 49,250
5 Aug 22 James H Stanker Common Stock Option exercise Acquire M No No 0 7,601 0 51,712
5 Aug 21 Wendy Guy Common Stock Payment of exercise Dispose F No No 3.17 1,782 5.65K 187,746
84.5% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 21 22 -4.5%
Opened positions 2 3 -33.3%
Closed positions 3 2 +50.0%
Increased positions 3 2 +50.0%
Reduced positions 3 6 -50.0%
13F shares Current Prev Q Change
Total value 52.2M 55.45M -5.9%
Total shares 13.4M 13.65M -1.8%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
David Young 11.44M $45.2M 0.0%
Yuhan (usa) 750K $2.96M 0.0%
Vanguard 373.6K $1.13M 0.0%
AIGH Capital Management 303.7K $915K 0.0%
Manchester Management 142.43K $819K 0.0%
Worth Venture Partners 70.95K $214K 0.0%
Geode Capital Management 64.9K $195K 0.0%
Verdence Capital Advisors 59.88K $180K -5.3%
Janney Montgomery Scott 46.23K $139K 0.0%
STT State Street 41.49K $125K 0.0%
Largest transactions Shares Bought/sold Change
Solas Capital Management 22.84K -173.31K -88.4%
Essex Investment Management 0 -73.18K EXIT
Vectors Research Management 0 -4K EXIT
Verdence Capital Advisors 59.88K -3.34K -5.3%
WFC Wells Fargo & Co. 3.14K +3.08K +4882.5%
Tower Research Capital 3.13K +1.52K +94.3%
BLK Blackrock 29.09K -1.41K -4.6%
UBS UBS Group AG - Registered Shares 1.12K +897 +411.5%
Whittier Trust 22 +22 NEW
BAC Bank Of America 0 -7 EXIT

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Continental, director, ensure, Equiniti, floor, hinder, modification, originally, put, rare, ratably, recommended, reelection, run, Trust, unamortized, unexpected, unknown
Removed: activate, assay, attributable, biomarker, continuing, depreciation, determining, existing, measurement, medicine, precision, refining, specifically